Abstract：Objective：To observe the clinical effect of Bufei Huayu prescription combined with gefitinib for non-small cell lung cancer(NSCLC) and its effects on immune function and levels of serum nitric oxide (NO) and vascular endothelial growth factor(VEGF). Methods： A total of 90 cases of patients who had advanced NSCLC with epidermal growth factor receptor(EGFR) gene mutation and of the lung- spleen qi deficiency type were selected and divided into the control group and the observation group according to the random number table method，with 45 cases in each group. The control group was treated with gefitinib， and the observation group was treated with Bufei Huayu tang and gefitinib. Chinese medicine syndrome scores， quality of life， levels of T lymphocyte in peripheral blood， and levels of NO and VEGF in serum before and after treatment，as well as clinical effects were compared between the two groups. Incidence of adverse reactions was observed. Results： The disease controlling rate was 71.11% in the observation group， higher than that of 44.44% in the control group， the difference being significant(P＜0.05). After treatment， Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment，and Karnofsky scores(KPS) in the two groups were increased(P＜0.05)；Chinese medicine syndrome score in the observation group was lower than that in the control group，and KPS score was higher(P＜0.05). After treatment，CD3+，CD4+，and CD4+/CD8+ in peripheral blood in the two groups were increased when compared with those before treatment，and CD8+ were decreased(P＜0.05)；CD3+， CD4 +，and CD4 +/CD8 + in peripheral blood in the observation group were higher than those in the control group，and CD8+ was lower(P＜0.05). After treatment，levels of NO and VEGF in serum in the two groups were decreased when compared with those before treatment(P＜0.05)， and the two levels in the observation group were lower than those in the control group(P＜0.05). The incidence of diarrhea，nausea and vomiting， rash and alopecia in the observation group was significantly lower than that in the control group(P＜0.05). Conclusion：Bufei Huayu tang combined with gefitinib has a defined curative effect in the treatment of NSCLC with EGFR gene mutation and of the lung- spleen qi deficiency type， which can improve clinical symptoms， immune function and quality of life， and reduce NO in serum， VEGF expression and toxic and side effects.